Patient and physician preferences for type 2 diabetes medications: a systematic review

被引:30
|
作者
Toroski, Mahdi [1 ]
Kebriaeezadeh, Abbas [1 ,2 ,3 ]
Esteghamati, Alireza [4 ]
Karyani, Ali Kazemi [5 ]
Abbasian, Hadi [1 ]
Nikfar, Shekoufeh [1 ]
机构
[1] Univ Tehran Med Sci, Dept Pharmacoecon & Pharmaceut Adm, Fac Pharm, Tehran, Iran
[2] Univ Tehran Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Tehran, Iran
[3] Univ Tehran Med Sci, Pharmaceut Sci Res Ctr, Tehran, Iran
[4] Univ Tehran Med Sci, Sch Med, Vali Asr Hosp, Endocrinol & Metab Res Ctr EMRC, Tehran, Iran
[5] Kermanshah Univ Med Sci, Sch Publ Hlth, Kermanshah, Iran
关键词
Patient preferences; Diabetes type 2; Physician; Systematic review; DISCRETE-CHOICE EXPERIMENT; WILLINGNESS-TO-PAY; ADHERENCE; MELLITUS; MANAGEMENT; PEOPLE; HEALTH; ATTRIBUTES; COMPLICATIONS; IMPROVEMENTS;
D O I
10.1007/s40200-019-00449-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background There are several treatments to cure type 2 diabetes (T2D) and every one of them has certain attributes which is lead patients and specialists to have different preferences and select power. Therefore, we did this systematic study to evaluate patients and physicians preferences for type 2 diabetes medications by extracting attributes of anti-diabetic medications and identifying their relative importance. Methods We searched the PubMed, Ovid, Web of science, Scopus and Embase databases for articles which have been published on or before May 8th, 2018(The start time of the search in our study was May 8th, 2018). Results The searches identified 3346 studies, of which 17 (from 2009 to 2017) were included in the final synthesis and 27 attributes of type 2 anti-diabetic have been investigated. The most important attributes are changes of blood glucose and HbA1c level, hypoglycemia events, weight changes, gastrointestinal complications, cardiovascular effects, medicines cost, and administration mode and dosage of medicines. Conclusion physicians and patients prefer antidiabetics which is reduce blood glucose and HbA1c level effectively and have low side effects too (hypoglycemic event, cardiovascular and gastrointestinal). The effect of weight reduction, low cost, low dosing and low frequency of using. Health care providers, Specialist, and manufacturers should consider to these attributes in treatment process and marketing. It can increase adherence to management approaches, and reduce morbidity of patients with type 2 diabetes.
引用
收藏
页码:643 / 656
页数:14
相关论文
共 50 条
  • [21] ADHERENCE OF PATIENTS WITH TYPE 2 DIABETES TO MEDICATIONS - THE ROLE OF RISK PREFERENCES
    Simon-Tuval, T.
    Shmueli, A.
    Harman-Boehm, I
    VALUE IN HEALTH, 2016, 19 (07) : A899 - A899
  • [22] A National Physician Survey of Deintensifying Diabetes Medications for Older Adults With Type 2 Diabetes
    Pilla, Scott J.
    Jalalzai, Rabia
    Tang, Olive
    Schoenborn, Nancy L.
    Boyd, Cynthia M.
    Golden, Sherita H.
    Mathioudakis, Nestoras N.
    Maruthur, Nisa M.
    DIABETES CARE, 2023, 46 (06) : 1164 - 1168
  • [23] Patient and Physician Factors Associated With Adherence to Diabetes Medications
    Schoenthaler, Antoinette M.
    Schwartz, Brian S.
    Wood, Craig
    Stewart, Walter F.
    DIABETES EDUCATOR, 2012, 38 (03): : 397 - 408
  • [24] Management of type 2 diabetes: a challenge for patient and physician
    van den Arend, IJM
    Stolk, RP
    Krans, HMJ
    Grobbee, DE
    Schrijvers, AJP
    PATIENT EDUCATION AND COUNSELING, 2000, 40 (02) : 187 - 194
  • [25] Physician-Patient Relationship in Type 2 Diabetes
    Bui, Thuy
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2012, 27 (10) : 1242 - 1242
  • [26] A systematic review of adherence with medications for diabetes
    Wens, J
    Vermeire, E
    Vermeire, E
    Van Royen, P
    Hearnshaw, H
    DIABETES CARE, 2004, 27 (09) : 2284 - 2284
  • [27] A systematic review of adherence with medications for diabetes
    Cramer, JA
    DIABETES CARE, 2004, 27 (05) : 1218 - 1224
  • [28] PATIENT PREFERENCES FOR THE TREATMENT OF TYPE-2 DIABETES: A SCOPING REVIEW AND ASSESSMENT OF METHODS
    Joy, S. M.
    Purnell, T. S.
    Little, E.
    Bridges, J. F.
    VALUE IN HEALTH, 2013, 16 (03) : A169 - A169
  • [29] Medications Affecting the Biochemical Conversion to Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Domecq, Juan Pablo
    Prutsky, Gabriela
    Elraiyah, Tarig
    Wang, Zhen
    Mauck, Karen F.
    Brito, Juan Pablo
    Undavalli, Chaitanya
    Sundaresh, Vishnu
    Prokop, Larry J.
    Montori, Victor M.
    Murad, M. Hassan
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (09): : 3986 - 3995
  • [30] Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States
    Kristina S. Boye
    Jessica B. Jordan
    Raleigh Malik
    Louis S. Matza
    Diabetes Therapy, 2024, 15 : 381 - 393